TY - JOUR
T1 - Blood Metabolomic Measures Associate With Present and Future Glycemic Control in Type 2 Diabetes
AU - 't Hart, Leen M.
AU - Vogelzangs, Nicole
AU - Mook-Kanamori, Dennis O.
AU - Brahimaj, Adela
AU - Nano, Jana
AU - van der Heijden, Amber A. W. A.
AU - van Dijk, Ko Willems
AU - Slieker, Roderick C.
AU - Steyerberg, Ewout W.
AU - Ikram, M. Arfan
AU - Beekman, Marian
AU - Boomsma, Dorret I.
AU - van Duijn, Cornelia M.
AU - Slagboom, P. Eline
AU - Stehouwer, Coen D. A.
AU - Schalkwijk, Casper G.
AU - Arts, Ilja C. W.
AU - Dekker, Jacqueline M.
AU - Dehghan, Abbas
AU - Muka, Taulant
AU - van der Kallen, Carla J. H.
AU - Nijpels, Giel
AU - van Greevenbroek, Marleen M. J.
PY - 2018/12
Y1 - 2018/12
N2 - Objective: We studied whether blood metabolomic measures in people with type 2 diabetes (T2D) are associated with insufficient glycemic control and whether this association is influenced differentially by various diabetes drugs. We then tested whether the same metabolomic profiles were associated with the initiation of insulin therapy.Methods: A total of 162 metabolomic measures were analyzed using a nuclear magnetic resonance-based method in people with T2D from four cohort studies (n = 2641) and one replication cohort (n = 395). Linear and logistic regression analyses with adjustment for potential confounders, followed by meta-analyses, were performed to analyze associations with hemoglobin A1c levels, six glucose-lowering drug categories, and insulin initiation during a 7-year follow-up period (n = 698).Results: After Bonferroni correction, 26 measures were associated with insufficient glycemic control (HbA1c >53 mmol/mol). The strongest association was with glutamine (OR, 0.66; 95% CI, 0.61 to 0.73; P = 7.6 x 10(-19)). In addition, compared with treatment-naive patients, 31 metabolomic measures were associated with glucose-lowering drug use (representing various metabolite categories; PConclusion: Blood metabolomic measures were associated with present and future glycemic control and might thus provide relevant cues to identify those at increased risk of treatment failure.
AB - Objective: We studied whether blood metabolomic measures in people with type 2 diabetes (T2D) are associated with insufficient glycemic control and whether this association is influenced differentially by various diabetes drugs. We then tested whether the same metabolomic profiles were associated with the initiation of insulin therapy.Methods: A total of 162 metabolomic measures were analyzed using a nuclear magnetic resonance-based method in people with T2D from four cohort studies (n = 2641) and one replication cohort (n = 395). Linear and logistic regression analyses with adjustment for potential confounders, followed by meta-analyses, were performed to analyze associations with hemoglobin A1c levels, six glucose-lowering drug categories, and insulin initiation during a 7-year follow-up period (n = 698).Results: After Bonferroni correction, 26 measures were associated with insufficient glycemic control (HbA1c >53 mmol/mol). The strongest association was with glutamine (OR, 0.66; 95% CI, 0.61 to 0.73; P = 7.6 x 10(-19)). In addition, compared with treatment-naive patients, 31 metabolomic measures were associated with glucose-lowering drug use (representing various metabolite categories; PConclusion: Blood metabolomic measures were associated with present and future glycemic control and might thus provide relevant cues to identify those at increased risk of treatment failure.
KW - MAGNETIC-RESONANCE METABOLOMICS
KW - INSULIN-RESISTANCE
KW - AMINO-ACIDS
KW - EPIDEMIOLOGY
KW - HYPERGLYCEMIA
KW - DETERMINANTS
KW - PROGRESSION
KW - PREDICT
KW - DESIGN
KW - RISK
U2 - 10.1210/jc.2018-01165
DO - 10.1210/jc.2018-01165
M3 - Article
C2 - 30113659
VL - 103
SP - 4569
EP - 4579
JO - Journal of Clinical Endocrinology & Metabolism
JF - Journal of Clinical Endocrinology & Metabolism
SN - 0021-972X
IS - 12
ER -